Advertisement
Advertisement
U.S. markets close in 4 hours 36 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Insig AI Plc (INSG.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
32.000.00 (0.00%)
As of 02:57PM BST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close32.00
Open32.50
Bid30.00 x N/A
Ask34.00 x N/A
Day's Range32.50 - 32.50
52 Week Range19.06 - 86.90
Volume50,000
Avg. Volume161,234
Market Cap33.816M
Beta (5Y Monthly)N/A
PE Ratio (TTM)64.00
EPS (TTM)0.50
Earnings DateDec 22, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for INSG.L

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Simply Wall St.

      Can Insig AI Plc's (LON:INSG) ROE Continue To Surpass The Industry Average?

      While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

    • GlobeNewswire

      Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

      Provides Protection and Highlights Novelty of BP1003 to Inhibit STAT3 Expression in a Variety of Difficult to Treat CancersHOUSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the United States Patent and Trademark Office has granted a new patent relating to the Company’s BP1003 p

    Advertisement
    Advertisement